AB-FUBICA
AB-FUBICA is a synthetic cannabinoid that has been identified as an ingredient in some herbal incense products. Synthetic cannabinoids are a class of chemicals that bind to the same receptors in the brain as tetrahydrocannabinol (THC), the active component in cannabis. However, synthetic cannabinoids can be much more potent and unpredictable in their effects compared to THC. AB-FUBICA was first reported in the scientific literature in 2013, and its chemical name is N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide.
Chemistry[edit | edit source]
AB-FUBICA is part of a larger group of synthetic cannabinoids known as indazole carboxamides. The structure of AB-FUBICA includes a fluorobenzyl group attached to an indazole base, with an additional amide group linking it to a valine derivative. This compound, like other synthetic cannabinoids, is designed to mimic the effects of THC by binding to the CB1 and CB2 cannabinoid receptors in the brain. However, the slight alterations in chemical structure can lead to significant differences in potency, efficacy, and safety profile.
Effects[edit | edit source]
The effects of AB-FUBICA, as with other synthetic cannabinoids, can vary widely among users but generally include psychoactive effects similar to those of cannabis, such as euphoria, relaxation, and altered perception. However, due to its potency and the variability of the compound's concentration in different products, users may also experience severe adverse effects. These can include anxiety, paranoia, hallucinations, and in extreme cases, seizures, severe psychotic episodes, and death.
Legal Status[edit | edit source]
The legal status of AB-FUBICA varies by country and jurisdiction. In response to the health risks posed by synthetic cannabinoids, many countries have moved to control these substances under drug control laws. AB-FUBICA has been listed as a controlled substance in several countries and regions, reflecting growing concern over the safety and potential for abuse of synthetic cannabinoids.
Health Risks[edit | edit source]
The health risks associated with the use of AB-FUBICA and similar synthetic cannabinoids are significant. Due to the lack of clinical trials and the unregulated nature of the market for these substances, the full extent of their health effects is not well understood. However, emergency room reports and toxicology studies have highlighted the potential for severe toxicity, including acute kidney injury, cardiovascular complications, and life-threatening psychiatric reactions.
Conclusion[edit | edit source]
AB-FUBICA is a potent synthetic cannabinoid that poses significant health risks to users. Its legal status in many countries reflects the growing awareness of the dangers associated with synthetic cannabinoids. Research into the effects and mechanisms of action of AB-FUBICA and similar compounds is ongoing, but the evidence to date underscores the need for caution among individuals considering the use of synthetic cannabinoid products.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD